Vilazodone is a modulator of serotonin neurotransmission to be used for treatment of Major Depression Disorders. Now there’s one more choice for depression, it’s amazing if you look how many of these are out there. BD
From the website:
“Nearly 2,900 patients have been exposed to vilazodone in the clinical development program. The efficacy of vilazodone in the treatment of MDD was shown to be superior to placebo in two randomized, double-blind, Phase III clinical trials. Results of an uncontrolled long-term safety study were consistent with the findings of the placebo-controlled studies. Discontinuation rates due to adverse events were low. The most common adverse events associated with vilazodone treatment were diarrhea, nausea and insomnia and considered mild to moderate in intensity. In addition, vilazodone’s impact on sexual function was shown to be similar to placebo when measured by quantitative, validated scales.”
SILVER SPRING, Md., Jan. 21, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.
Major depressive disorder, also called major depression, is characterized by symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Episodes of major depression often recur throughout a person's lifetime, although some may experience only a single occurrence.
Signs and symptoms of major depression include: depressed mood, loss of interest in usual activities, significant change in weight or appetite, insomnia or excessive sleeping (hypersomnia), restlessness/pacing (psychomotor agitation), increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicide attempts or thoughts of suicide. All people with major depression do not experience the same symptoms.
FDA Approves Viibryd to Treat Major Depressive Disorder -- SILVER SPRING, Md., Jan. 21, 2011 /PRNewswire-USNewswire/ --
It will be interesting to see how quickly doctors embrace (or don't embrace) this drug considering the stiff competition from more established drugs that do the same thing.ReplyDelete